News | February 22, 2022
Asahi Kasei to build new production unit for membrane virus filters in Japan
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
AIIA partners with Startup India with the aim to identify and support innovations and start-ups working in the Ayush sector
Essential products manufactured by Sartorius, using Sü dpack polymer films made from Dow resins, support safe and effective vaccine production for global vaccine supply
CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades
The partnership is already underway having launched earlier last week, and the contract could be worth up to £211 million.
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
Subscribe To Our Newsletter & Stay Updated
